Success Metrics

Active Trials
3(50%)

Phase Distribution

Ph not_applicable
1
17%
Ph phase_1
1
17%
Ph phase_2
4
67%

Phase Distribution

1

Early Stage

4

Mid Stage

0

Late Stage

Phase Distribution6 total trials
Phase 1Safety & dosage
1(16.7%)
Phase 2Efficacy & side effects
4(66.7%)
N/ANon-phased studies
1(16.7%)

Highest Phase Reached

Phase 2

Trial Status & Enrollment

Completion Rate

0.0%

0 of 0 finished

Non-Completion Rate

0.0%

0 ended early

Currently Active

3

trials recruiting

Total Trials

6

all time

Status Distribution
Active(5)
Other(1)

Detailed Status

Recruiting3
Not yet recruiting2
unknown1

Development Timeline

Analytics

Development Status

Total Trials
6
Active
3
Success Rate
N/A
Most Advanced
Phase 2

Trials by Phase

Phase 11 (16.7%)
Phase 24 (66.7%)
N/A1 (16.7%)

Trials by Status

not_yet_recruiting233%
recruiting350%
unknown117%

Recent Activity

3 active trials
Showing 5 of 6
recruitingphase_2

Neoadjuvant ChemoRadiotherapy Followed by Immunotherapy and Surgery for Resectable Esophageal Squamous Cell Carcinoma（CRIS-2 Trial）

NCT06509568
not_yet_recruitingphase_2

Neoadjuvant Immunochemotherapy and Postoperative Adjuvant Immunotherapy for Head and Neck Squamous Cell Carcinoma Invading the Skull Base

NCT07145931
recruitingphase_1

NEoadjuvant Chemotherapy and Immunotherapy for a Selected Group of Inoperable Pleural Mesothelioma Patients (NECIM): a Feasibility Study

NCT07121374
not_yet_recruitingnot_applicable

Pucotenlimab Combined With Chemotherapy as Perioperative Treatment for Locally Advanced Gastroesophageal Junction Carcinoma

NCT07092449
recruitingphase_2

Study of Tislelizumab for Locally Advanced Non-Small Cell Lung Cancer Following Neoadjuvant Chemotherapy Plus Tislelizumab ± Bevacizumab and Definitive Concurrent Chemoradiation Therapy

NCT05468242
View all 6 trials

Clinical Trials (6)

Showing 6 of 6 trials
NCT06509568Phase 2

Neoadjuvant ChemoRadiotherapy Followed by Immunotherapy and Surgery for Resectable Esophageal Squamous Cell Carcinoma（CRIS-2 Trial）

Recruiting
NCT07145931Phase 2

Neoadjuvant Immunochemotherapy and Postoperative Adjuvant Immunotherapy for Head and Neck Squamous Cell Carcinoma Invading the Skull Base

Not Yet Recruiting
NCT07121374Phase 1

NEoadjuvant Chemotherapy and Immunotherapy for a Selected Group of Inoperable Pleural Mesothelioma Patients (NECIM): a Feasibility Study

Recruiting
NCT07092449Not Applicable

Pucotenlimab Combined With Chemotherapy as Perioperative Treatment for Locally Advanced Gastroesophageal Junction Carcinoma

Not Yet Recruiting
NCT05468242Phase 2

Study of Tislelizumab for Locally Advanced Non-Small Cell Lung Cancer Following Neoadjuvant Chemotherapy Plus Tislelizumab ± Bevacizumab and Definitive Concurrent Chemoradiation Therapy

Recruiting
NCT02976142Phase 2

The Efficacy of Surgical Treatment After Neoadjuvant Chemotherapy Plus Intraperitoneal Immunotherapy Versus Chemotherapy Alone for Patients With Positive Wash Cytology Gastric Cancer

Unknown

All 6 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
6